anti-B-Cell CLL/lymphoma 11B (Zinc Finger Protein) (BCL11B) Antibodies

BCL11B encodes a C2H2-type zinc finger protein and is closely related to BCL11A, a gene whose translocation may be associated with B-cell malignancies. Additionally we are shipping BCL11B Kits (7) and and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
BCL11B 58208 Q99PV8
BCL11B 64919 Q9C0K0
BCL11B 314423  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-BCL11B Antibodies at

Showing 10 out of 64 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-BCL11B Antibody Titration: 0.2-1 ug/ml ELISA Titer: 1:62500 Positive Control: Jurkat cell lysate BCL11B is supported by BioGPS gene expression data to be expressed in Jurkat 100 μL 2 to 3 Days
Cow Rabbit Un-conjugated IHC, WB WB Suggested Anti-BCL11B Antibody Titration:  0.2-1 ug/ml  ELISA Titer:  1:12500  Positive Control:  THP-1 cell lysate 100 μL 2 to 3 Days
Cow Rabbit Un-conjugated WB Host: Rabbit Target Name: BCL11B Sample Type: 293T Whole Cell lysates Antibody Dilution: 1.0ug/ml 100 μL 2 to 3 Days
Human Rabbit Un-conjugated EIA, WB BCL11B Antibody (Center) western blot analysis in K562 cell line lysates (35µg/lane).This demonstrates the BCL11B antibody detected the BCL11B protein (arrow). 0.4 mL 6 to 8 Days
Bat Rabbit Un-conjugated IHC, IHC (p), WB Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE) Anti-BCL11B antibody IHC of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other fo ... 100 μL 11 to 14 Days
Bat Rabbit Un-conjugated WB 100 μL 11 to 14 Days
Human Mouse Un-conjugated ELISA, FACS, WB Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Western blot analysis using BCL11B mAb against human BCL11B (AA: 1-150) recombinant protein. (Expected MW is 42.3 kDa) 0.1 mg 3 to 4 Days
Human Mouse Un-conjugated ELISA, FACS, ICC, IHC, WB Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Western blot analysis using BCL11B mAb against human BCL11B (AA: 1-150) recombinant protein. (Expected MW is 42.3 kDa) 0.1 mg 3 to 4 Days
Human Rabbit Un-conjugated WB Western Blot at 1:16000 dilution Lane 1: Jurkat whole cell lysate Lane 2: MOLT-4 whole cell lysate Lysates/proteins at 20 ug per lane. 400 μL 2 to 3 Days
Human Rabbit Un-conjugated ELISA, IHC, WB Western blot analysis of BCL11B expression in Jurkat cell lysate,The lane on the left is treated with the antigen-specific peptide. ABIN6273594 at 1/100 staining Rat heart tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. 100 μL 11 to 12 Days

Top referenced anti-BCL11B Antibodies

  1. Human Polyclonal BCL11B Primary Antibody for ICC, IF - ABIN251041 : Beguin, Crépel, Aniksztejn, Becq, Pelosi, Pallesi-Pocachard, Bouamrane, Pasqualetti, Kitamura, Cardoso, Represa: An epilepsy-related ARX polyalanine expansion modifies glutamatergic neurons excitability and morphology without affecting GABAergic neurons development. in Cerebral cortex (New York, N.Y. : 1991) 2013 (PubMed)
    Show all 3 Pubmed References

  2. Human Polyclonal BCL11B Primary Antibody for ICC, IF - ABIN4283768 : Wang, Sun, Fang, Ho, Yang, Tzeng: Function of B-Cell CLL/Lymphoma 11B in Glial Progenitor Proliferation and Oligodendrocyte Maturation. in Frontiers in molecular neuroscience 2018 (PubMed)

  3. Human Polyclonal BCL11B Primary Antibody for ICC, IF - ABIN153204 : Matsumoto, Nagoshi, Yoshida, Kato, Kuroda, Shimura, Kaneko, Horiike, Nakamura, Taniwaki: Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma. in Internal medicine (Tokyo, Japan) 2018 (PubMed)

More Antibodies against BCL11B Interaction Partners

Mouse (Murine) B-Cell CLL/lymphoma 11B (Zinc Finger Protein) (BCL11B) interaction partners

  1. Bcl11b controls both GATA3-mediated gene activation and repression in Th2 cells.

  2. We show that Bcl11b in pro-T cells blocked expression of the E-protein antagonist Id2 (encoded by Id2) and the innate-response regulator PLZF (encoded by Zbtb16).

  3. stimulation of MAP kinase and (or) Wnt signaling pathways differentially affects gene expression of some Bcl11b target and maturation-associated genes.

  4. Study identified the maturation enhancer E4m, validated its role in regulating CD4 expression, and isolate Bcl11b as an important activator for E4m.

  5. Mice lacking Bcl11b in mature T-cells have a diminished capacity to mount Th2 responses during helminth infection and allergic asthma, showing reduced Th2 cytokines and Gata3, and elevated Runx3.

  6. Thus, this study identifies BCL11B as a novel regulator of adipogenesis, which works, at least in part, by stimulating C/EBPbeta activity and suppressing the Wnt/beta-catenin signaling pathway.

  7. Bcl11b is associated with cell fate in the T-cell gene regulatory network.

  8. Bcl11b, known as a T-lineage commitment factor, is essential for proper expression of ThPOK and Runx3, central regulators for the CD4-helper/CD8-cytotoxic lineage choice.

  9. Authors provide insight into the mechanism that underpins the repositioning of regulatory elements; identify a non-coding RNA, named ThymoD, which acts to reposition the Bcl11 enhancer away from the lamina to the nuclear interior and sequester the Bcl11b promoter and enhancer region into a single-loop domain.

  10. key regulator of Invariant natural killer T-cell effector subsets, their function, identity, and survival

  11. these results suggest that Bcl11b acts as a central intrinsic regulator of mammary epithelial stem cell quiescence.

  12. BCL11B is expressed in both osteogenic and sutural mesenchyme of the developing craniofacial complex. Bcl11b(-/-) mice exhibit increased proliferation of osteoprogenitors, premature osteoblast differentiation, and enhanced skull mineralization leading to synostoses of facial and calvarial sutures.

  13. this study shows that distinct, asynchronous and stage-specific transcription factors (TCF-1, GATA-3 and Runx1) activate Bcl11b for T cell commitment

  14. the expression and function of Bcl11b in the oral epithelium and demonstration that Bcl11b is an essential regulator for keratinocyte differentiation and the morphogenesis of papillary structure of the lingual epithelium.

  15. BCL11B as a regulator of energy metabolism

  16. Data uncover for the first time a specific role of Bcl11b in adult hippocampal neurogenesis and function.

  17. BCL11B is extensively expressed in neocortical GABAergic interneurons of all three major subgroups and thus its expression is not restricted to subcerebral projections cells.

  18. Bcl11b regulates development of different thymocyte subsets at multiple stages and prevents an excess of innate CD8 single-positive thymocytes.

  19. sustains mature Type 2 innate lymphoid cells genetic and functional programs and lineage fidelity

  20. Data indicate kinetic changes in relative phosphorylation on 18 of 23 serine and threonine residues and sumoylation on one of two lysine resides in B-cell lymphoma-leukemia 11B protein BCL11B.

Human B-Cell CLL/lymphoma 11B (Zinc Finger Protein) (BCL11B) interaction partners

  1. Results confirm the BCL11B dimerization hypothesis and prove its importance for BCL11B function. By mapping the relevant regions to the CCHC domain, authors describe a previously unidentified mechanism of transcription factor homodimerization.

  2. BCL11B regulates mammary cell differentiation.

  3. These results suggest that the upregulation of miR-650 contributes to the development of acute renal allograft rejection by suppression of BCL11B, which leads to apoptosis and inflammatory responses. Thus, miR-650 and BCL11B may represent potential therapeutic targets for the prevention of acute renal allograft rejection.

  4. In this present work, the authors identify and characterize a transcription factor i.e. HIC1, which physically interacts with both Bcl11b/CTIP2 and HMGA1 to co-regulate specific subsets of cellular genes and the HIV-1 tat gene.

  5. Decreased transcript and increased promoter methylation levels of BCL11B gene were identified in ankylosing spondylitis patients.

  6. this is the first study to show that the inhibition of Bcl11b suppresses glioma cell growth by regulating the expression of the cell cycle regulator p21 and stemness-associated genes (Sox-2/Bmi-1).

  7. studies show BCL11B is a key regulator of the initial stages of human T-cell differentiation and delineate the BCL11B transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL

  8. BCL11B showed increased but varied expression in advanced tumor stage. Analysis of four patients receiving SAHA treatment suggested a positive correlation between BCL11B expression and favorable response to SAHA treatment. In conclusion, BCL11B may serve as a therapeutic target and a useful marker for improving HDACi efficacy in advanced CTCL.

  9. Human T-cell leukemia virus type 1 (HTLV-1) Tax directly binds to BCL11B. Tax enhances BCL11B degradation through proteasome pathway. Loss of BCL11B enhances cell growth in HTLV-1-infected cells.

  10. Findings identify BCL11B Ser2 phosphorylation as a new mandatory step in the interconnected posttranslational modifications converting BCL11B from a transcriptional repressor to an activator.

  11. BCL11B introduction in human cell lines downregulated transcription of beta-catenin target genes, whereas Bcl11b attenuation in Lgr5(+) crypt base columnar cells increased expression of beta-catenin targets including c-Myc and cyclin D1.

  12. Tax is responsible for suppressing BCL11B protein expression in HTLV-1-infected T-cells; Tax-mediated repression of BCL11B is another mechanism that Tax uses to promote oncogenesis of HTLV-1-infected T-cells.

  13. low BCL11b expression was associated with poor prognosis; particularly in the standard risk group of thymic T-cell acute lymphoblastic leukemia

  14. Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.

  15. a comprehensive review of the roles of Bcl11b in progenitors, effector T cells, regulatory T cells, and invariant NKT cells, as well as its impact on immune diseases.

  16. overexpressed in mycosis fungoides lesions

  17. CTIP2 controls P-TEFb function in physiological and pathological conditions.

  18. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.

  19. a reduction in the level of the BCL11B protein is a key event in the multistep progression of ATLL leukemogenesis

  20. BLC11B is an oncogene in T-ALL pathogenesis.

BCL11B Antigen Profile

Protein Summary

This gene encodes a C2H2-type zinc finger protein and is closely related to BCL11A, a gene whose translocation may be associated with B-cell malignancies. The specific function of this gene has not yet been determined. Two alternatively spliced transcript variants, which encode distinct isoforms, have been reported.

Gene names and symbols associated with BCL11B

  • B-cell CLL/lymphoma 11B (BCL11B) antibody
  • B cell leukemia/lymphoma 11B (Bcl11b) antibody
  • B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11B) antibody
  • B-cell CLL/lymphoma 11B (Bcl11b) antibody
  • 9130430L19Rik antibody
  • AI604821 antibody
  • ATL1 antibody
  • ATL1-alpha antibody
  • ATL1-beta antibody
  • ATL1-delta antibody
  • ATL1-gamma antibody
  • B630002E05Rik antibody
  • BCL-11B antibody
  • BCL11B antibody
  • CTIP-2 antibody
  • CTIP2 antibody
  • hRIT1-alpha antibody
  • RIT1 antibody
  • ZNF856B antibody

Protein level used designations for BCL11B

B-cell CLL/lymphoma 11B (zinc finger protein) , B-cell CLL/lymphoma 11B , B-cell CLL/lymphoma 11B, isoform 1 , B-cell leukemia/lymphoma 11B , B-cell lymphoma/leukaemia 11B , B-cell lymphoma/leukemia 11B , COUP-TF interacting protein 2 , COUP-TF-interacting protein 2 , mRit1 , radiation-induced tumor suppressor gene 1 protein , B-cell CLL/lymphoma 11B/T-cell receptor delta constant region fusion protein , BCL-11B , BCL11B/TRDC fusion , hRit1 , zinc finger protein hRit1 alpha , B-cell lymphoma/leukemia 11B (predicted), 3 prime , B-cell lymphoma/leukemia 11B (predicted), 5 prime , COUP-TF-interacting protein 2 long form

423444 Gallus gallus
467548 Pan troglodytes
100137584 Papio anubis
58208 Mus musculus
64919 Homo sapiens
612476 Canis lupus familiaris
783269 Bos taurus
100328694 Oryctolagus cuniculus
314423 Rattus norvegicus
Selected quality suppliers for anti-BCL11B (BCL11B) Antibodies
Did you look for something else?